Celldex Therapeutics Analyst Ratings
Celldex Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/03/2023 | 96.37% | Cantor Fitzgerald | $54 → $52 | Maintains | Overweight |
| 10/12/2023 | 103.93% | Cantor Fitzgerald | → $54 | Reiterates | Overweight → Overweight |
| 09/27/2023 | 103.93% | Cantor Fitzgerald | → $54 | Reiterates | Overweight → Overweight |
| 08/22/2023 | -20.69% | Wells Fargo | → $21 | Initiates Coverage On | → Underweight |
| 08/16/2023 | 103.93% | Cantor Fitzgerald | → $54 | Reiterates | Overweight → Overweight |
| 08/10/2023 | 175.68% | HC Wainwright & Co. | → $73 | Reiterates | Buy → Buy |
| 08/09/2023 | 175.68% | HC Wainwright & Co. | → $73 | Reiterates | Buy → Buy |
| 06/12/2023 | 175.68% | HC Wainwright & Co. | → $73 | Reiterates | Buy → Buy |
| 05/31/2023 | 175.68% | HC Wainwright & Co. | → $73 | Reiterates | → Buy |
| 05/05/2023 | 103.93% | Cantor Fitzgerald | $55 → $54 | Maintains | Overweight |
| 05/05/2023 | 175.68% | HC Wainwright & Co. | → $73 | Reiterates | → Buy |
| 03/22/2023 | 175.68% | HC Wainwright & Co. | → $73 | Reiterates | → Buy |
| 03/01/2023 | 175.68% | HC Wainwright & Co. | → $73 | Reiterates | → Buy |
| 02/27/2023 | 175.68% | HC Wainwright & Co. | → $73 | Reiterates | → Buy |
| 11/11/2022 | 137.92% | Guggenheim | $68 → $63 | Maintains | Buy |
| 08/09/2022 | 141.69% | SVB Leerink | $68 → $64 | Maintains | Outperform |
| 07/01/2022 | 175.68% | HC Wainwright & Co. | $60 → $73 | Maintains | Buy |
| 09/17/2021 | 149.24% | Jefferies | → $66 | Initiates Coverage On | → Buy |
| 09/13/2021 | 126.59% | HC Wainwright & Co. | $54 → $60 | Maintains | Buy |
| 09/10/2021 | 156.8% | SVB Leerink | → $68 | Initiates Coverage On | → Outperform |
| 08/06/2021 | 103.93% | HC Wainwright & Co. | $50 → $54 | Maintains | Buy |
| 07/22/2021 | 149.24% | Guggenheim | → $66 | Initiates Coverage On | → Buy |
| 07/12/2021 | 88.82% | HC Wainwright & Co. | $36 → $50 | Maintains | Buy |
| 02/23/2021 | 35.95% | HC Wainwright & Co. | $25 → $36 | Maintains | Buy |
| 10/19/2020 | -5.59% | HC Wainwright & Co. | $16 → $25 | Maintains | Buy |
| 03/27/2020 | -39.58% | HC Wainwright & Co. | $19 → $16 | Reiterates | → Buy |
| 02/21/2020 | -69.79% | Cantor Fitzgerald | → $8 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/03/2023 | 96.37% | 坎托·菲茨杰拉德 | 54 美元 → 52 美元 | 维护 | 超重 |
| 2023 年 12 月 10 日 | 103.93% | 坎托·菲茨杰拉德 | → 54 美元 | 重申 | 超重 → 超重 |
| 09/27/2023 | 103.93% | 坎托·菲茨杰拉德 | → 54 美元 | 重申 | 超重 → 超重 |
| 08/22/2023 | -20.69% | 富国银行 | → 21 美元 | 启动覆盖范围开启 | → 体重不足 |
| 08/16/2023 | 103.93% | 坎托·菲茨杰拉德 | → 54 美元 | 重申 | 超重 → 超重 |
| 08/10/2023 | 175.68% | HC Wainwright & Co. | → 73 美元 | 重申 | 购买 → 购买 |
| 08/09/2023 | 175.68% | HC Wainwright & Co. | → 73 美元 | 重申 | 购买 → 购买 |
| 06/12/2023 | 175.68% | HC Wainwright & Co. | → 73 美元 | 重申 | 购买 → 购买 |
| 05/31/2023 | 175.68% | HC Wainwright & Co. | → 73 美元 | 重申 | → 购买 |
| 05/05/2023 | 103.93% | 坎托·菲茨杰拉德 | 55 美元 → 54 美元 | 维护 | 超重 |
| 05/05/2023 | 175.68% | HC Wainwright & Co. | → 73 美元 | 重申 | → 购买 |
| 03/22/2023 | 175.68% | HC Wainwright & Co. | → 73 美元 | 重申 | → 购买 |
| 03/01/2023 | 175.68% | HC Wainwright & Co. | → 73 美元 | 重申 | → 购买 |
| 02/27/2023 | 175.68% | HC Wainwright & Co. | → 73 美元 | 重申 | → 购买 |
| 11/11/2022 | 137.92% | 古根海姆 | 68 美元 → 63 美元 | 维护 | 买 |
| 08/09/2022 | 141.69% | SVB Leerink | 68 美元 → 64 美元 | 维护 | 跑赢大盘 |
| 2022 年 1 月 7 日 | 175.68% | HC Wainwright & Co. | 60 美元 → 73 美元 | 维护 | 买 |
| 09/17/2021 | 149.24% | 杰富瑞集团 | → 66 美元 | 启动覆盖范围开启 | → 购买 |
| 09/13/2021 | 126.59% | HC Wainwright & Co. | 54 美元 → 60 美元 | 维护 | 买 |
| 2021 年 10 月 9 日 | 156.8% | SVB Leerink | → 68 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 08/06/2021 | 103.93% | HC Wainwright & Co. | 50 美元 → 54 美元 | 维护 | 买 |
| 07/22/2021 | 149.24% | 古根海姆 | → 66 美元 | 启动覆盖范围开启 | → 购买 |
| 07/12/2021 | 88.82% | HC Wainwright & Co. | 36 美元 → 50 美元 | 维护 | 买 |
| 2021 年 2 月 23 日 | 35.95% | HC Wainwright & Co. | 25 美元 → 36 美元 | 维护 | 买 |
| 2020 年 10 月 19 日 | -5.59% | HC Wainwright & Co. | 16 美元 → 25 美元 | 维护 | 买 |
| 03/27/2020 | -39.58% | HC Wainwright & Co. | 19 美元 → 16 美元 | 重申 | → 购买 |
| 02/21/2020 | -69.79% | 坎托·菲茨杰拉德 | → 8 美元 | 启动覆盖范围开启 | → 超重 |
What is the target price for Celldex Therapeutics (CLDX)?
Celldex Therapeutics（CLDX）的目标价格是多少？
The latest price target for Celldex Therapeutics (NASDAQ: CLDX) was reported by Cantor Fitzgerald on November 3, 2023. The analyst firm set a price target for $52.00 expecting CLDX to rise to within 12 months (a possible 96.37% upside). 15 analyst firms have reported ratings in the last year.
坎托·菲茨杰拉德于2023年11月3日公布了Celldex Therapeutics（纳斯达克股票代码：CLDX）的最新目标股价。该分析公司将目标股价定为52.00美元，预计CLDX将在12个月内升至12个月内（可能上涨96.37％）。去年有15家分析公司公布了评级。
What is the most recent analyst rating for Celldex Therapeutics (CLDX)?
分析师对Celldex Therapeutics（CLDX）的最新评级是多少？
The latest analyst rating for Celldex Therapeutics (NASDAQ: CLDX) was provided by Cantor Fitzgerald, and Celldex Therapeutics maintained their overweight rating.
Celldex Therapeutics（纳斯达克股票代码：CLDX）的最新分析师评级由坎托·菲茨杰拉德提供，Celldex Therapeutics维持增持评级。
When is the next analyst rating going to be posted or updated for Celldex Therapeutics (CLDX)?
Celldex Therapeutics（CLDX）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Celldex Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Celldex Therapeutics was filed on November 3, 2023 so you should expect the next rating to be made available sometime around November 3, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Celldex Therapeutics的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Celldex Therapeutics的最新评级是在2023年11月3日公布的，因此您应该预计下一个评级将在2024年11月3日左右公布。
Is the Analyst Rating Celldex Therapeutics (CLDX) correct?
分析师对 Celldex Therapeutics (CLDX) 的评级正确吗？
While ratings are subjective and will change, the latest Celldex Therapeutics (CLDX) rating was a maintained with a price target of $54.00 to $52.00. The current price Celldex Therapeutics (CLDX) is trading at is $26.48, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Celldex Therapeutics（CLDX）评级维持不变，目标股价为54.00美元至52.00美元。Celldex Therapeutics（CLDX）目前的交易价格为26.48美元，超出了分析师的预期区间。